Literature DB >> 19731305

Sacrocolpopexy using xenogenic acellular collagen in patients at increased risk for graft-related complications.

Filip Claerhout1, Dirk De Ridder, Dirk Van Beckevoort, Georges Coremans, Joan Veldman, Paul Lewi, Jan Deprest.   

Abstract

AIMS: We studied the long-term anatomical and functional outcome following sacrocolpopexy for apical vaginal prolapse using xenogenic grafts in a population at increased risk for graft-related complications (GRCs).
METHODS: Twenty-two consecutive patients with symptomatic apical prolapse were scheduled for laparoscopic sacrocolpopexy (LSC) with porcine grafts because they were presumed to be at risk for GRC, because of pre-existing vaginal ulcerations (n = 4), concomitant vaginal prolapse repair (n = 15), total hysterectomy (n = 1), or intra-operative abdominal contamination due to accidental laceration of the vagina, bowel perforation (n = 1) or the presence of infection (n = 1). Either small intestinal submucosa (n = 8) or dermal collagen (n = 14) was used. Outcome measures were GRCs, anatomical cure (<or=Stage I at any compartment), subjective cure, impact on bowel, bladder, and sexual function measured by a standardized interview.
RESULTS: At study closure 20 (91%) patients were available for functional evaluation and 16 (73%) for anatomical evaluation at a mean follow-up period of 27.4 months. The GRC rate was 25% (n = 4) prompting reintervention in half, and including two patients with spondylodiscitis. The anatomical cure rate was 31.5%. Failures at the vault, anterior, and posterior compartments occurred in, respectively, 31%, 18.8%, and 50% of patients. The subjective cure rate was 60% and three patients (15%) underwent redo-LSC.
CONCLUSION: The strategy of using xenografts in patients at risk for GRC, did not prevent these to occur and was associated with a high anatomical and functional failure rate as well as reoperation rate. (c) 2009 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 19731305     DOI: 10.1002/nau.20805

Source DB:  PubMed          Journal:  Neurourol Urodyn        ISSN: 0733-2467            Impact factor:   2.696


  7 in total

1.  Surgical interventions for uterine prolapse and for vault prolapse: the two VUE RCTs.

Authors:  Christine Hemming; Lynda Constable; Beatriz Goulao; Mary Kilonzo; Dwayne Boyers; Andrew Elders; Kevin Cooper; Anthony Smith; Robert Freeman; Suzanne Breeman; Alison McDonald; Suzanne Hagen; Isobel Montgomery; John Norrie; Cathryn Glazener
Journal:  Health Technol Assess       Date:  2020-03       Impact factor: 4.014

Review 2.  Tissue engineering as a potential alternative or adjunct to surgical reconstruction in treating pelvic organ prolapse.

Authors:  M Boennelycke; S Gras; G Lose
Journal:  Int Urogynecol J       Date:  2012-09-01       Impact factor: 2.894

3.  Analysis of the learning process for laparoscopic sacrocolpopexy: identification of challenging steps.

Authors:  Filip Claerhout; Jasper Verguts; Erika Werbrouck; Joan Veldman; Paul Lewi; Jan Deprest
Journal:  Int Urogynecol J       Date:  2014-05-21       Impact factor: 2.894

4.  Laparoscopic ventral rectopexy using biologic mesh for the treatment of obstructed defaecation syndrome and/or faecal incontinence in patients with internal rectal prolapse: a critical appraisal of the first 100 cases.

Authors:  L Franceschilli; D Varvaras; I Capuano; C I Ciangola; F Giorgi; G Boehm; A L Gaspari; P Sileri
Journal:  Tech Coloproctol       Date:  2015-01-11       Impact factor: 3.781

Review 5.  Apical prolapse.

Authors:  Matthew D Barber; Christopher Maher
Journal:  Int Urogynecol J       Date:  2013-11       Impact factor: 2.894

Review 6.  To mesh or not to mesh: a review of pelvic organ reconstructive surgery.

Authors:  Patrick Dällenbach
Journal:  Int J Womens Health       Date:  2015-04-01

7.  Electrospun Nanofiber Meshes With Endometrial MSCs Modulate Foreign Body Response by Increased Angiogenesis, Matrix Synthesis, and Anti-Inflammatory Gene Expression in Mice: Implication in Pelvic Floor.

Authors:  Shayanti Mukherjee; Saeedeh Darzi; Kallyanashis Paul; Fiona L Cousins; Jerome A Werkmeister; Caroline E Gargett
Journal:  Front Pharmacol       Date:  2020-03-24       Impact factor: 5.810

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.